JP2025020148A5 - - Google Patents

Download PDF

Info

Publication number
JP2025020148A5
JP2025020148A5 JP2024179270A JP2024179270A JP2025020148A5 JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5 JP 2024179270 A JP2024179270 A JP 2024179270A JP 2024179270 A JP2024179270 A JP 2024179270A JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5
Authority
JP
Japan
Prior art keywords
receptor antagonist
crf
molecular weight
use according
low molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024179270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025020148A (ja
Filing date
Publication date
Priority claimed from JP2019572817A external-priority patent/JP7398963B2/ja
Application filed filed Critical
Publication of JP2025020148A publication Critical patent/JP2025020148A/ja
Publication of JP2025020148A5 publication Critical patent/JP2025020148A5/ja
Pending legal-status Critical Current

Links

JP2024179270A 2017-08-14 2024-10-11 副腎皮質刺激ホルモン放出因子受容体拮抗薬 Pending JP2025020148A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545406P 2017-08-14 2017-08-14
US62/545,406 2017-08-14
JP2019572817A JP7398963B2 (ja) 2017-08-14 2018-08-14 副腎皮質刺激ホルモン放出因子受容体拮抗薬
PCT/US2018/046760 WO2019036503A1 (en) 2017-08-14 2018-08-14 CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
JP2023146415A JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023146415A Division JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Publications (2)

Publication Number Publication Date
JP2025020148A JP2025020148A (ja) 2025-02-12
JP2025020148A5 true JP2025020148A5 (https=) 2025-03-05

Family

ID=65362494

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019572817A Active JP7398963B2 (ja) 2017-08-14 2018-08-14 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2023146415A Active JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2024179270A Pending JP2025020148A (ja) 2017-08-14 2024-10-11 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019572817A Active JP7398963B2 (ja) 2017-08-14 2018-08-14 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2023146415A Active JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Country Status (11)

Country Link
US (9) US20210361664A1 (https=)
EP (1) EP3628005A4 (https=)
JP (3) JP7398963B2 (https=)
KR (2) KR20200040761A (https=)
CN (2) CN110996943A (https=)
AU (2) AU2018317398A1 (https=)
BR (1) BR112020002967A2 (https=)
CA (1) CA3064464A1 (https=)
EA (1) EA202090450A1 (https=)
MX (2) MX2019015320A (https=)
WO (1) WO2019036503A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65839B1 (sr) 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) * 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) * 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよび使用方法
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
AU713673B2 (en) 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
EA004403B1 (ru) 1996-07-24 2004-04-29 Дюпон Фармасьютикалз Компани Производные пиразолотриазинов, фармацевтические композиции, содержащие их, способы лечения
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
IL137019A (en) 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
ATE301657T1 (de) 1998-01-28 2005-08-15 Bristol Myers Squibb Pharma Co Azolo-pyrimidine
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
ES2277855T3 (es) 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
PL351069A1 (en) 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
NZ528207A (en) 2001-03-13 2006-02-24 Bristol Myers Squibb Pharma Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
US20050085479A1 (en) 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
EP1708790B1 (en) 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
MY143499A (en) 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
WO2005079807A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
EP1722826A2 (en) 2004-02-13 2006-11-22 SB Pharmco Puerto Rico Inc. Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP1869049B1 (en) 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds
CN101516835A (zh) 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
JP5184536B2 (ja) 2006-09-20 2013-04-17 イーライ リリー アンド カンパニー チオフェンピラゾロピリミジン化合物
HRP20100516T1 (hr) 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
US8952207B2 (en) 2007-09-11 2015-02-10 The University Of Houston System Copper-catalyzed C—H bond arylation
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
DK2350079T3 (da) 2008-10-02 2012-12-17 Lilly Co Eli Thiazolylpyrazolopyrimidinforbindelser som syntetiske mellemprodukter og dertil relaterede syntetiske fremgangsmåder
EP4718074A2 (en) * 2008-12-24 2026-04-01 Quest Diagnostics Investments Incorporated Mass spectrometry assay for congenital adrenal hyperplasia
EP2682111A1 (en) * 2009-12-31 2014-01-08 Differential Drug Development Associates LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
AU2013230781B2 (en) 2012-03-08 2015-12-03 Medtronic Af Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US20150094310A1 (en) 2012-04-23 2015-04-02 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
RS65839B1 (sr) * 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
AU2016242867B2 (en) 2015-03-31 2020-11-05 May Health Us Inc. Methods and systems for the manipulation of ovarian tissues
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
JP7285222B2 (ja) 2017-08-14 2023-06-01 スプルース バイオサイエンシズ インコーポレイテッド 副腎皮質刺激ホルモン放出因子受容体拮抗薬
EP4643950A3 (en) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US20200255436A1 (en) 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
JP2022541550A (ja) 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
JP2024539907A (ja) 2021-11-19 2024-10-31 スプルース バイオサイエンシーズ，インク． チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Similar Documents

Publication Publication Date Title
JP2025020148A5 (https=)
JP2022541550A5 (https=)
Sitruk-Ware et al. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills
JP2656958B2 (ja) ホルモン依存性腫瘍治療剤
CN102811730B (zh) 孕激素作为糖皮质激素增敏剂的使用
Sitruk-Ware et al. The use of newer progestins for contraception
Africander et al. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception
Schindler et al. Reprint of classification and pharmacology of progestins
Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Sitruk-Ware Pharmacology of different progestogens: the special case of drospirenone
Fruzzetti et al. Review of clinical experience with estradiol in combined oral contraceptives
Kaore et al. Novel actions of progesterone: what we know today and what will be the scenario in the future?
JP2013518908A5 (https=)
IL286048B2 (en) Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation
CA2326654A1 (en) Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
Requena et al. Oral contraceptives in dermatology
CN103298343A (zh) 类固醇和糖皮质激素受体拮抗剂组合疗法
Voutsadaki et al. Hypogonadism in adolescent girls: treatment and long-term effects
Tatsumi et al. Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins
AU2015256473B2 (en) Formulations and methods for vaginal delivery of antiprogestins
JP2008534533A5 (https=)
JP6343619B2 (ja) プロゲステロン依存性病態を処置する方法およびその組成物
Noori et al. Effects of estrogen and progesterone used in oral contraceptive pills: A review
EP2026818B1 (en) Combination of steroids having transporter-enhanced corticosteroid activity
US20020156059A1 (en) Pharmaceutical combination preparations that contain aromatase inhibitors and substances with estrogenic action as well as their use